BioCryst's peramivir may get new life, despite 'stop-work' order
This article was originally published in Scrip
Executive Summary
Shares of rollercoaster-riding BioCryst Pharmaceuticals zoomed upward as high as 37% on 1 April after the company said its previously thought doomed intravenous flu antiviral peramivir may have new life after the US FDA provided hope for a path forward in the form of a "preliminary comment letter."